A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. SUKHWINDER KAUR			
AGE/ GENDER	: 50 YRS/FEMALE	РАТ	TIENT ID	: 1619113
COLLECTED BY	:	REG	G. NO./LAB NO.	: 122409200009
REFERRED BY	:	REG	SISTRATION DATE	: 20/Sep/2024 08:58 AM
BARCODE NO.	: 12504815	COI	LECTION DATE	: 20/Sep/2024 09:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INST	ITUTE Rep	PORTING DATE	: 20/Sep/2024 04:35PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AM	BALA CITY - HARYA	NA	
Test Name		Value	Unit	Biological Reference interva
	GLYC	HAEMATC OSYLATED HAEM	DLOGY Oglobin (HBA1C)	
NHOLE BLOOD by HPLC (HIGH PERFO STIMATED AVERAGI by HPLC (HIGH PERFO	MOGLOBIN (HbA1c): rmance liquid chromatography)			4.0 - 6.4 60.00 - 140.00
WHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERAGI by HPLC (HIGH PERFO	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY)	OSYLATED HAEM 8.4 ^H 194.38 ^H	OGLOBIN (HBA1C) % mg/dL	4.0 - 6.4
NHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERAGI by HPLC (HIGH PERFO <u>NTERPRETATION:</u>	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY)	OSYLATED HAEM 8.4 ^H 194.38 ^H DIABETES ASSOCIATIO	OGLOBIN (HBA1C) % mg/dL	4.0 - 6.4 60.00 - 140.00
NHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERAGI by HPLC (HIGH PERFO INTERPRETATION: F Non dia	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years	OSYLATED HAEM 8.4 ^H 194.38 ^H DIABETES ASSOCIATIO	OGLOBIN (HBA1C) % mg/dL N (ADA): SYLATED HEMOGLOGIB <5.7	4.0 - 6.4 60.00 - 140.00
NHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERAGI by HPLC (HIGH PERFO INTERPRETATION: F Non dia At	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years t Risk (Prediabetes)	OSYLATED HAEM 8.4 ^H 194.38 ^H DIABETES ASSOCIATIO	OGLOBIN (HBA1C) % mg/dL N (ADA): SYLATED HEMOGLOGIB <5.7 5.7 - 6.4	4.0 - 6.4 60.00 - 140.00
NHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERAGI by HPLC (HIGH PERFO <u>NTERPRETATION:</u> F Non dia At	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years	OSYLATED HAEM 8.4 ^H 194.38 ^H DIABETES ASSOCIATIO	OGLOBIN (HBA1C) % mg/dL N (ADA): SYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5	4.0 - 6.4 60.00 - 140.00
NHOLE BLOOD by HPLC (HIGH PERFO STIMATED AVERAGI by HPLC (HIGH PERFO <u>NTERPRETATION:</u> F Non dia At	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years t Risk (Prediabetes)	OSYLATED HAEM 8.4 ^H 194.38 ^H DIABETES ASSOCIATIO GLYCO	OGLOBIN (HBA1C) % mg/dL N (ADA): SYLATED HEMOGLOGIB <5.7 5.7 - 6.4 >= 6.5 Age > 19 Years	4.0 - 6.4 60.00 - 140.00 3 (HBAIC) in %
NHOLE BLOOD by HPLC (HIGH PERFO ESTIMATED AVERAGI by HPLC (HIGH PERFO INTERPRETATION: F Non dia At Di	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years t Risk (Prediabetes)	OSYLATED HAEM 8.4 ^H 194.38 ^H DIABETES ASSOCIATIO GLYCO Goals of T	OGLOBIN (HBA1C) % mg/dL N (ADA): SYLATED HEMOGLOGIB <5.7 5.7 – 6.4 >= 6.5 Age > 19 Years herapy:	4.0 - 6.4 60.00 - 140.00 3 (HBAIC) in %
ESTIMATED AVERAGI by HPLC (HIGH PERFO INTERPRETATION: F Non dia At Di	MOGLOBIN (HbA1c): RMANCE LIQUID CHROMATOGRAPHY) E PLASMA GLUCOSE RMANCE LIQUID CHROMATOGRAPHY) AS PER AMERICAN I REFERENCE GROUP abetic Adults >= 18 years t Risk (Prediabetes) iagnosing Diabetes	OSYLATED HAEM 8.4 ^H 194.38 ^H DIABETES ASSOCIATIO GLYCO	OGLOBIN (HBA1C) % mg/dL N (ADA): SYLATED HEMOGLOGIB <5.7 5.7 – 6.4 >= 6.5 Age > 19 Years herapy:	4.0 - 6.4 60.00 - 140.00 3 (HBAIC) in %

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients. 2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

4. High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

NOT VALID FOR MEDICO LEGAL PURPOSE



A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. SUKHWINDER KAUR			
AGE/ GENDER	: 50 YRS/FEMALE		PATIENT ID	: 1619113
COLLECTED BY	:		REG. NO./LAB NO.	: 122409200009
REFERRED BY			REGISTRATION DATE	: 20/Sep/2024 08:58 AM
BARCODE NO.	: 12504815		COLLECTION DATE	: 20/Sep/2024 09:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INS'	TITUTE	REPORTING DATE	: 20/Sep/2024 01:36PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AM	/IBALA CITY - HA	ARYANA	
Test Name		Value	Unit	Biological Reference interval
	CLINI	CAL CHEMIS	STRY/BIOCHEMISTRY	(
		LIPID PR	OFILE : BASIC	
CHOLESTEROL TOTA by CHOLESTEROL O		261.76 ^H	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.
TRIGLYCERIDES: SEF by GLYCEROL PHOSE	RUM phate oxidase (enzymatic)	213.96 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (by SELECTIVE INHIBIT		53.06	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: 5 by CALCULATED, SPE		165.91 ^H	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTE by calculated, spi		208.7 ^H	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189. HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: by CALCULATED, SPE		42.79	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERU by CALCULATED, SPE		737.48 ^H	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL by CALCULATED, SPE		4.93 ^H	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**



Page 2 of 6

NAME : Mrs. SUKHWINDER KAUR **AGE/ GENDER** : 50 YRS/FEMALE **PATIENT ID** :1619113 **COLLECTED BY** : 122409200009 REG. NO./LAB NO. **REFERRED BY REGISTRATION DATE** : 20/Sep/2024 08:58 AM **BARCODE NO. COLLECTION DATE** : 20/Sep/2024 09:54AM :12504815 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE **REPORTING DATE** : 20/Sep/2024 01:36PM **CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

Test Name	Value Unit		Biological Reference interval
LDL/HDL RATIO: SERUM by calculated, spectrophotometry	3.13 ^H	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	4.03	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
 NLA_2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along

with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDI

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana) A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. SUKHWINDER KAUR				
AGE/ GENDER	: 50 YRS/FEMALE	PAT	IENT ID	: 1619113	
COLLECTED BY	:	REG	. NO./LAB NO.	: 122409200009	
REFERRED BY	:	REG	ISTRATION DATE	: 20/Sep/2024 08:58 AM	
BARCODE NO.	: 12504815	COL	LECTION DATE	: 20/Sep/2024 09:54AM	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INST	TITUTE REP	ORTING DATE	: 20/Sep/2024 05:45PM	
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AM	BALA CITY - HARYAN	JA		
Test Name		Value	Unit	Biological Reference interval	
		IRON PRO	DFILE		
IRON: SERUM	TROPHOTOMETRY	37.05	μg/dL	37.0 - 145.0	
UNSATURATED IRON SERUM by FERROZINE, SPEC	I BINDING CAPACITY (UIBC)	212.45	μg/dL	150.0 - 336.0	
TOTAL IRON BINDIN SERUM		249.5	μg/dL	230 - 430	

IRON: SERUM by FERROZINE, SPECTROPHOTOMETRY	37.05	μg/dL	37.0 - 145.0	
UNSATURATED IRON BINDING CAPA		μg/dL	150.0 - 336.0	
by FERROZINE, SPECTROPHOTOMETER			000 400	
TOTAL IRON BINDING CAPACITY (TIB :SERUM by SPECTROPHOTOMETERY	3C) 249.5	μg/dL	230 - 430	
%TRANSFERRIN SATURATION: SERU by calculated, spectrophotometer	17.00	KR %	15.0 - 50.0	
TRANSFERRIN: SERUM by SPECTROPHOTOMETERY (FERENE)	177.15 ^L	mg/dL	200.0 - 350.0	
INTERPRETATION:-				
VARIABLES	ANEMIA OF CHRONIC DISEASE	IRON DEFICIENCY ANEMIA	THALASSEMIA α/β TRAIT	
SERUM IRON:	Normal to Reduced	Reduced	Normal	

% TRANSFERRIN SATURATI	ON:
SERUM FERRITIN:	

IRON:

1.Serum iron studies is recommended for differential diagnosis of microcytic hypochromic anemia.i.e iron deficiency anemia, zinc deficiency anemia, anemia of chronic disease and thalassemia syndromes.

Increased

Decreased < 12-15 %

Decreased

Normal

Normal

Normal or Increased

2. It is essential to isolate iron deficiency anemia from Beta thalassemia syndromes because during iron replacement which is therapeutic for iron deficiency anemia, is severely contra-indicated in Thalassemia.

TOTAL IRON BÍNDING CAPACITY (TÍBC):

TOTAL IRON BINDING CAPACITY:

1.It is a direct measure of protein transferrin which transports iron from the gut to storage sites in the bone marrow.

Decreased

Decreased

Normal to Increased

% TRANSFERRIN SATURATION:

1.Occurs in idiopathic hemochromatosis and transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of transferrin.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. SUKHWINDER KAUR					
AGE/ GENDER	: 50 YRS/FEMALE	PATIENT	' ID	: 1619113		
COLLECTED BY	:	REG. NO.	/LAB NO.	: 122409200009		
REFERRED BY	:	REGISTR	ATION DATE	: 20/Sep/2024 08:58 AM		
BARCODE NO.	: 12504815	COLLECT	ION DATE	: 20/Sep/2024 09:54AM		
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORT	ING DATE	: 20/Sep/2024 01:36PM		
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA C	CITY - HARYANA		×	T. T	
Test Name		alue	Unit	Biological Refere	ence interval	
		VITAMINS				
	VITA	MIN B12/COBA				
VITAMIN B12/COBA	LAMIN: SERUM 63			200 - 940		
	LAMIN: SERUM 63	36.01	pg/mL	200 - 940		
				200 - 940		
by CMIA (CHEMILUMIN INTERPRETATION:-		36.01				
by CMIA (CHEMILUMIN INTERPRETATION:-	IESCENT MICROPARTICLE IMMUNOASSAY)	36.01	pg/mL			
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS	IESCENT MICROPARTICLE IMMUNOASSAY) SED VITAMIN B12 nin C	36.01 	pg/mL	B12		
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan	SED VITAMIN B12 hin C gen hin A	36.01 DEC 1.Pregnancy	pg/mL	B12		
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan 4.Hepatocellular in	SED VITAMIN B12 hin C gen hin A jury	36.01 <u>DEC</u> <u>1.Pregnancy</u> <u>2.DRUGS:Aspirin, /</u> <u>3.Ethanol Igestion</u> <u>4. Contraceptive H</u>	pg/mL REASED VITAMIN	B12		
by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan	SED VITAMIN B12 hin C gen hin A jury	36.01 DEC 1.Pregnancy 2.DRUGS:Aspirin, / 3.Ethanol Igestion	pg/mL REASED VITAMIN Anti-convulsants, armones	B12		

2.In humans, it is obtained only from animal proteins and requires intrinsic factor (IF) for absorption.

3. The body uses its vitamin B12 stores very economically, reabsorbing vitamin B12 from the ileum and returning it to the liver; very little is excreted

4. Vitamin B12 deficiency may be due to lack of IF secretion by gastric mucosa (eg, gastrectomy, gastric atrophy) or intestinal malabsorption (eg, ileal resection, small intestinal diseases).

5. Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes. These manifestations may occur in any combination; many patients have the neurologic defects without macrocytic anemia.

6.Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.

7. Follow-up testing for antibodies to intrinsic factor (IF) is recommended to identify this potential cause of vitamin B12 malabsorption. NOTE: A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mrs. SUKHWINDER KAUI	2		
AGE/ GENDER	: 50 YRS/FEMALE	P	ATIENT ID	: 1619113
COLLECTED BY	:	R	EG. NO./LAB NO.	: 122409200009
REFERRED BY	:	R	EGISTRATION DATE	: 20/Sep/2024 08:58 AM
BARCODE NO.	: 12504815	C	OLLECTION DATE	: 20/Sep/2024 09:54AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE IN	NSTITUTE REPORTING DATE		: 20/Sep/2024 04:50PM
CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY -			ANA	
Test News		Malaa	11 14	Distantiast Defenses internet
Test Name		Value	Unit	Biological Reference interval
		VITAMIN B9/FOI	LIC ACID/FOLATE	
	ACID/FOLATE: SERUM SESCENCE IMMUNOASSAY)	13.9	ng/mL	DEFICIENT: < 3.37 INTERMEDIATE: 3.37 - 5.38 NORMAL: > 5.38
INTERPRETATION				
	PESI II T IN na/ml		DEMUDICS	

RESULT IN ng/mL REMARKS 0.35 - 3.37 DEFICIENT 3.38 - 5.38 INTERMEDIATE 5.39 - 100.00 NORMAL

NOTE:

1. Drugs like Methotrexate & Leucovorin interfere with folate measurement

2. To differentiate vitamin B12 & folate deficiency, measurement of Methyl malonic acid in urine & serum Homocysteine level is suggested 3. Risk of toxicity from folic acid is low as it is a water soluble vitamin regularly excreted in urine

COMMENTS:

1. Folate plays an important role in the synthesis of purine & pyrimidines in the body and is important for the maturation of erythrocytes.

It is widely available from plants and to a lesser extent organ meats, but more than half the folate content of food is lost during cooking.
 Folate deficiency is commonly prevalent in alcoholic liver disease, pregnancy and the elderly. It may result from poor intestinal absorption, nutrition deficiency, excessive demand as in pregnancy or in malignancy and in response to certain drugs like Methotrexate & anticonvulsants.
 Decreased Levels Megaloblastic anemia, Infantile hyperthyroidism, Alcoholism, Malnutrition, Scurvy, Liver disease, B12 deficiency, dietary amino acid excess, adult Celiac disease, Tropical Sprue, Crohn's disease, Hemolytic anemias, Carcinomas, Myelofibrosis, vitamin B6 deficiency, pregnancy, Whipple's disease, extensive intestinal resection and severe exfoliative dermatitis

*** End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

